Top

Published in:

01-03-2005 | Review

The role of the T cell in autoimmune inflammation

Authors: Alla Skapenko, Jan Leipe, Peter E Lipsky, Hendrik Schulze-Koops

Published in: Arthritis Research & Therapy | Special Issue 2/2005

Abstract

T cells, in particular CD4⁺ T cells, have been implicated in mediating many aspects of autoimmune inflammation. However, current evidence suggests that the role played by CD4⁺ T cells in the development of rheumatoid inflammation exceeds that of activated proinflammatory T-helper (Th)1 effector cells that drive the chronic autoimmune response. Subsets of CD4⁺ T cells with regulatory capacity, such as CD25⁺ regulatory T (Treg) cells and Th2 cells, have been identified, and recent observations suggest that in rheumatoid arthritis the function of these regulatory T cells is severely impaired. Thus, in rheumatoid arthritis, defective regulatory mechanisms might allow the breakdown of peripheral tolerance, after which the detrimental Th1-driven immune response evolves and proceeds to chronic inflammation. Here, we review the functional abnormalities and the contribution of different T cell subsets to rheumatoid inflammation.

Germain RN: T-cell development and the CD4-CD8 lineage decision. Nat Rev Immunol. 2002, 2: 309-322.PubMed

Spits H: Development of alphabeta T cells in the human thymus. Nat Rev Immunol. 2002, 2: 760-772.PubMed

Weiss A: T cell antigen receptor signal transduction: a tale of tails and cytoplasmic protein-tyrosine kinases. Cell. 1993, 73: 209-212.PubMed

Chan AC, Iwashima M, Turck CW, Weiss A: ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell. 1992, 71: 649-662.PubMed

Jacobs MR, Haynes BF: Increase in TCR gamma delta T lymphocytes in synovia from rheumatoid arthritis patients with active synovitis. J Clin Immunol. 1992, 12: 130-138.PubMed

Olive C, Gatenby PA, Serjeantson SW: Evidence for oligoclonality of T cell receptor delta chain transcripts expressed in rheumatoid arthritis patients. Eur J Immunol. 1992, 22: 2587-2593.PubMed

June CH, Bluestone JA, Nadler LM, Thompson CB: The B7 and CD28 receptor families. Immunol Today. 1994, 15: 321-331.PubMed

Lindsten T, June CH, Ledbetter JA, Stella G, Thompson CB: Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science. 1989, 244: 339-343.

Fraser JD, Irving BA, Crabtree GR, Weiss A: Regulation of inter-leukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science. 1991, 251: 313-316.PubMed

10.

Li-Weber M, Giasi M, Krammer PH: Involvement of Jun and Rel proteins in up-regulation of interleukin-4 gene activity by the T cell accessory molecule CD28. J Biol Chem. 1998, 273: 32460-32466.PubMed

11.

Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Lindsten T, Thompson CB: CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity. 1995, 3: 87-98.PubMed

12.

Alegre ML, Noel PJ, Eisfelder BJ, Chuang E, Clark MR, Reiner SL, Thompson CB: Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J Immunol. 1996, 157: 4762-4770.PubMed

13.

Cerdan C, Martin Y, Courcoul M, Brailly H, Mawas C, Birg F, Olive D: Prolonged IL-2 receptor alpha/CD25 expression after T cell activation via the adhesion molecules CD2 and CD28. Demonstration of combined transcriptional and post-transcriptional regulation. J Immunol. 1992, 149: 2255-2261.PubMed

14.

Yin D, Zhang L, Wang R, Radvanyi L, Haudenschild C, Fang Q, Kehry MR, Shi Y: Ligation of CD28 In vivo induces CD40 ligand expression and promotes B cell survival. J Immunol. 1999, 163: 4328-4334.PubMed

15.

Arai K, Yamamura S, Seki S, Hanyu T, Takahashi HE, Abo T: Increase of CD57⁺ T cells in knee joints and adjacent bone marrow of rheumatoid arthritis (RA) patients: implication for an anti-inflammatory role. Clin Exp Immunol. 1998, 111: 345-352.PubMedCentralPubMed

16.

Wang EC, Lawson TM, Vedhara K, Moss PA, Lehner PJ, Borysiewicz LK: CD8high⁺ (CD57⁺) T cells in patients with rheumatoid arthritis. Arthritis Rheum. 1997, 40: 237-248.PubMed

17.

Hingorani R, Monteiro J, Furie R, Chartash E, Navarrete C, Pergolizzi R, Gregersen PK: Oligoclonality of V beta 3 TCR chains in the CD8⁺ T cell population of rheumatoid arthritis patients. J Immunol. 1996, 156: 852-858.PubMed

18.

Fazou C, Yang H, McMichael AJ, Callan MF: Epitope specificity of clonally expanded populations of CD8⁺ T cells found within the joints of patients with inflammatory arthritis. Arthritis Rheum. 2001, 44: 2038-2045.PubMed

19.

Berner B, Akca D, Jung T, Muller GA, Reuss-Borst MA: Analysis of Th1 and Th2 cytokines expressing CD4⁺ and CD8⁺ T cells in rheumatoid arthritis by flow cytometry. J Rheumatol. 2000, 27: 1128-1135.PubMed

20.

Kang YM, Zhang X, Wagner UG, Yang H, Beckenbaugh RD, Kurtin PJ, Goronzy JJ, Weyand CM: CD8 T cells are required for the formation of ectopic germinal centers in rheumatoid synovitis. J Exp Med. 2002, 195: 1325-1336.PubMedCentralPubMed

21.

Wagner UG, Kurtin PJ, Wahner A, Brackertz M, Berry DJ, Goronzy JJ, Weyand CM: The role of CD8⁺ CD40L⁺ T cells in the formation of germinal centers in rheumatoid synovitis. J Immunol. 1998, 161: 6390-6397.PubMed

22.

Ehinger M, Vestberg M, Johansson AC, Johannesson M, Svens-son A, Holmdahl R: Influence of CD4 or CD8 deficiency on collagen-induced arthritis. Immunology. 2001, 103: 291-300.PubMedCentralPubMed

23.

Taneja V, Taneja N, Paisansinsup T, Behrens M, Griffiths M, Luthra H, David CS: CD4 and CD8 T cells in susceptibility/protection to collagen-induced arthritis in HLA-DQ8-transgenic mice: implications for rheumatoid arthritis. J Immunol. 2002, 168: 5867-5875.PubMed

24.

Van Boxel JA, Paget SA: Predominantly T-cell infiltrate in rheumatoid synovial membranes. N Engl J Med. 1975, 293: 517-520.PubMed

25.

Banerjee S, Webber C, Poole AR: The induction of arthritis in mice by the cartilage proteoglycan aggrecan: roles of CD4⁺ and CD8⁺ T cells. Cell Immunol. 1992, 144: 347-357.PubMed

26.

Breedveld FC, Dynesius-Trentham R, de Sousa M, Trentham DE: Collagen arthritis in the rat is initiated by CD4⁺ T cells and can be amplified by iron. Cell Immunol. 1989, 121: 1-12.PubMed

27.

Panayi GS, Tugwell P: The use of cyclosporin A in rheumatoid arthritis: conclusions of an international review. Br J Rheumatol. 1994, 33: 967-969.PubMed

28.

Paulus HE, Machleder HI, Levine S, Yu DT, MacDonald NS: Lymphocyte involvement in rheumatoid arthritis. Studies during thoracic duct drainage. Arthritis Rheum. 1977, 20: 1249-1262.PubMed

29.

Strober S, Tanay A, Field E, Hoppe RT, Calin A, Engleman EG, Kotzin B, Brown BW, Kaplan HS: Efficacy of total lymphoid irradiation in intractable rheumatoid arthritis. A double-blind, randomized trial. Ann Intern Med. 1985, 102: 441-449.PubMed

30.

Calin A, Elswood J, Klouda PT: Destructive arthritis, rheumatoid factor, and HLA-DR4. Susceptibility versus severity, a case-control study. Arthritis Rheum. 1989, 32: 1221-1225.PubMed

31.

Winchester R: The molecular basis of susceptibility to rheumatoid arthritis. Adv Immunol. 1994, 56: 389-466.PubMed

32.

Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986, 136: 2348-2357.PubMed

33.

Abbas AK, Murphy KM, Sher A: Functional diversity of helper T lymphocytes. Nature. 1996, 383: 787-793.PubMed

34.

Rocken M, Saurat JH, Hauser C: A common precursor for CD4⁺ T cells producing IL-2 or IL-4. J Immunol. 1992, 148: 1031-1036.PubMed

35.

Da Silva JA, Spector TD: The role of pregnancy in the course and aetiology of rheumatoid arthritis. Clin Rheumatol. 1992, 11: 189-194.PubMed

36.

Mishan-Eisenberg G, Borovsky Z, Weber MC, Gazit R, Tykocinski ML, Rachmilewitz J: Differential regulation of Th1/Th2 cytokine responses by placental protein 14. J Immunol. 2004, 173: 5524-5530.PubMed

37.

Verhoef CM, van Roon JA, Vianen ME, Bruijnzeel-Koomen CA, Lafeber FP, Bijlsma JW: Mutual antagonism of rheumatoid arthritis and hay fever; a role for type 1/type 2 T cell balance. Ann Rheum Dis. 1998, 57: 275-280.PubMedCentralPubMed

38.

Ioannou Y, Isenberg DA: Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000, 43: 1431-1442.PubMed

39.

Peeva E, Fishman AD, Goddard G, Wadler S, Barland P: Rheumatoid arthritis exacerbation caused by exogenous interleukin-12. Arthritis Rheum. 2000, 43: 461-463.PubMed

40.

Miltenburg AM, van Laar JM, de Kuiper R, Daha MR, Breedveld FC: T cells cloned from human rheumatoid synovial membrane functionally represent the Th1 subset. Scand J Immunol. 1992, 35: 603-610.PubMed

41.

Quayle AJ, Chomarat P, Miossec P, Kjeldsen-Kragh J, Forre O, Natvig JB: Rheumatoid inflammatory T-cell clones express mostly Th1 but also Th2 and mixed (Th0) cytokine patterns. Scand J Immunol. 1993, 38: 75-82.PubMed

42.

Kusaba M, Honda J, Fukuda T, Oizumi K: Analysis of type 1 and type 2 T cells in synovial fluid and peripheral blood of patients with rheumatoid arthritis. J Rheumatol. 1998, 25: 1466-1471.PubMed

43.

Canete JD, Martinez SE, Farres J, Sanmarti R, Blay M, Gomez A, Salvador G, Munoz-Gomez J: Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. Ann Rheum Dis. 2000, 59: 263-268.PubMedCentralPubMed

44.

Davis LS, Cush JJ, Schulze-Koops H, Lipsky PE: Rheumatoid synovial CD4⁺ T cells exhibit a reduced capacity to differentiate into IL-4-producing T-helper-2 effector cells. Arthritis Res. 2001, 3: 54-64.PubMedCentralPubMed

45.

van der Graaff WL, Prins AP, Niers TM, Dijkmans BA, van Lier RA: Quantitation of interferon gamma- and interleukin-4-producing T cells in synovial fluid and peripheral blood of arthritis patients. Rheumatology. 1999, 38: 214-220.PubMed

46.

Miyata M, Ohira H, Sasajima T, Suzuki S, Ito M, Sato Y, Kasukawa R: Significance of low mRNA levels of interleukin-4 and -10 in mononuclear cells of the synovial fluid of patients with rheumatoid arthritis. Clin Rheumatol. 2000, 19: 365-370.PubMed

47.

Schulze-Koops H, Lipsky PE, Kavanaugh AF, Davis LS: Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis: modulation by treatment with anti-ICAM-1 correlates with clinical benefit. J Immunol. 1995, 155: 5029-5037.PubMed

48.

Kanik KS, Hagiwara E, Yarboro CH, Schumacher HR, Wilder RL, Klinman DM: Distinct patterns of cytokine secretion characterize new onset synovitis versus chronic rheumatoid arthritis. J Rheumatol. 1998, 25: 16-22.PubMed

49.

Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C: Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med. 2004, 200: 277-285.PubMedCentralPubMed

50.

Cao D, Malmstrom V, Baecher-Allan C, Hafler D, Klareskog L, Trollmo C: Isolation and functional characterization of regulatory CD25brightCD4⁺ T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol. 2003, 33: 215-23.PubMed

51.

Weiner HL: Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. Microbes Infect. 2001, 3: 947-954.PubMed

52.

Cao D, van Vollenhoven R, Klareskog L, Trollmo C, Malmstrom V: CD25brightCD4⁺ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther. 2004, 6: R335-R346.PubMedCentralPubMed

53.

Groux H, O'Garra A, Bigler M, Rouleau M, Antonenko S, de Vries JE, Roncarolo MG: A CD4⁺ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997, 389: 737-742.PubMed

54.

Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995, 155: 1151-1164.PubMed

55.

McHugh RS, Shevach EM: Cutting edge: depletion of CD4⁺CD25⁺ regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease. J Immunol. 2002, 168: 5979-5983.PubMed

56.

Mottet C, Uhlig HH, Powrie F: Cutting edge: cure of colitis by CD4⁺CD25⁺ regulatory T cells. J Immunol. 2003, 170: 3939-3943.PubMed

57.

Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN: Human anergic/suppressive CD4⁺CD25⁺ T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol. 2001, 31: 1122-1131.PubMed

58.

Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH: Identification and functional characterization of human CD4⁺CD25⁺ T cells with regulatory properties isolated from peripheral blood. J Exp Med. 2001, 193: 1285-1294.PubMedCentralPubMed

59.

Levings MK, Sangregorio R, Roncarolo MG: Human CD25⁺CD4⁺ T regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med. 2001, 193: 1295-1302.PubMedCentralPubMed

60.

Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G: Ex vivo isolation and characterization of CD4⁺CD25⁺ T cells with regulatory properties from human blood. J Exp Med. 2001, 193: 1303-1310.PubMedCentralPubMed

61.

Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA: CD4⁺CD25high regulatory cells in human peripheral blood. J Immunol. 2001, 167: 1245-1253.PubMed

62.

Stephens LA, Mottet C, Mason D, Powrie F: Human CD4⁺CD25⁺ thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol. 2001, 31: 1247-1254.PubMed

63.

Annunziato F, Cosmi L, Liotta F, Lazzeri E, Manetti R, Vanini V, Romagnani P, Maggi E, Romagnani S: Phenotype, localization, and mechanism of suppression of CD4⁺CD25⁺ human thymo-cytes. J Exp Med. 2002, 196: 379-387.PubMedCentralPubMed

64.

Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH: Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol. 2002, 168: 4272-4276.PubMed

65.

Thornton AM, Shevach EM: CD4⁺CD25⁺ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998, 188: 287-296.PubMedCentralPubMed

66.

Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S: Immunologic self-tolerance maintained by CD25⁺CD4⁺ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000, 192: 303-310.PubMedCentralPubMed

67.

McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, Byrne MC: CD4⁺CD25⁺ immunoregulatory T cells: gene expression analysis reveals a functional role for the glu-cocorticoid-induced TNF receptor. Immunity. 2002, 16: 311-323.PubMed

68.

Hori S, Takahashi T, Sakaguchi S: Control of autoimmunity by naturally arising regulatory CD4⁺ T cells. Adv Immunol. 2003, 81: 331-371.PubMed

69.

Piccirillo CA, Shevach EM: Naturally-occurring CD4⁺CD25⁺ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin Immunol. 2004, 16: 81-88.PubMed

70.

van Amelsfort JM, Jacobs KM, Bijlsma JW, Lafeber FP, Taams LS: CD4⁺CD25⁺ regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum. 2004, 50: 2775-2785.PubMed

71.

van Amelsfort JM, Noordegraaf M, Bijlsma JWJ, Taams LS, Lafeber FPJG: Influence of the inflammatory milieu on the suppressive function of CD4⁺CD25⁺ T cells in rheumatoid arthritis. Arthritis Rheum. 2004, 50: S526-

72.

Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM: Development of TH1 CD4⁺ T cells through IL-12 produced by Listeria -induced macrophages. Science. 1993, 260: 547-549.PubMed

73.

Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, Van Eden W, Van Der Zee R, Biedermann T, Prinz J, Mack M, et al: Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med. 2003, 9: 40-46.PubMed

74.

Horsfall AC, Butler DM, Marinova L, Warden PJ, Williams RO, Maini RN, Feldmann M: Suppression of collagen-induced arthritis by continuous administration of IL-4. J Immunol. 1997, 159: 5687-5696.PubMed

75.

Miossec P, Chomarat P, Dechanet J, Moreau JF, Roux JP, Delmas P, Banchereau J: Interleukin-4 inhibits bone resorption through an effect on osteoclasts and proinflammatory cytokines in an ex vivo model of bone resorption in rheumatoid arthritis. Arthritis Rheum. 1994, 37: 1715-1722.PubMed

76.

Miossec P, Briolay J, Dechanet J, Wijdenes J, Martinez-Valdez H, Banchereau J: Inhibition of the production of proinflammatory cytokines and immunoglobulins by interleukin-4 in an ex vivo model of rheumatoid synovitis. Arthritis Rheum. 1992, 35: 874-883.PubMed

77.

Hidaka T, Kitani A, Hara M, Harigai M, Suzuki K, Kawaguchi Y, Ishizuka T, Kawagoe M, Nakamura H: IL-4 down-regulates the surface expression of CD5 on B cells and inhibits spontaneous immunoglobulin and IgM-rheumatoid factor production in patients with rheumatoid arthritis. Clin Exp Immunol. 1992, 89: 223-229.PubMedCentralPubMed

78.

Skapenko A, Wendler J, Lipsky PE, Kalden JR, Schulze-Koops H: Altered memory T cell differentiation in patients with early rheumatoid arthritis. J Immunol. 1999, 163: 491-499.PubMed

79.

Schulze-Koops H, Lipsky PE: Anti-CD4 monoclonal antibody therapy in human autoimmune diseases. Curr Dir Autoimmun. 2000, 2: 24-49.PubMed

80.

Schulze-Koops H, Kalden JR: Targeting T cells in rheumatic diseases. Biological Therapy in Rheumatology. Edited by: Smolen JS, Lipsky PE. 2003, London: Martin Dunitz Publishers, 3-24.

81.

Panayi GS: Targeting of cells involved in the pathogenesis of rheumatoid arthritis. Rheumatology. 1999, 38 (Suppl 2): 8-10.PubMed

82.

Yocum DE: T cells: pathogenic cells and therapeutic targets in rheumatoid arthritis. Semin Arthritis Rheum. 1999, 29: 27-35.PubMed

83.

Joosten LA, Lubberts E, Helsen MM, Saxne T, Coenende Roo CJ, Heinegard D, van den Berg WB: Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis. Arthritis Res. 1999, 1: 81-91.PubMedCentralPubMed

84.

Bessis N, Boissier MC, Ferrara P, Blankenstein T, Fradelizi D, Fournier C: Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete inter-leukin-13. Eur J Immunol. 1996, 26: 2399-2403.PubMed

85.

Bruneau JM, Yea CM, Spinella-Jaegle S, Fudali C, Woodward K, Robson PA, Sautes C, Westwood R, Kuo EA, Williamson RA, Ruuth E: Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 the active metabolite of leflunomide. Biochem J. 1726, 336: 299-303.

86.

Dimitrova P, Skapenko A, Herrmann ML, Schleyerbach R, Kalden JR, Schulze-Koops H: Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation. J Immunol. 2002, 169: 3392-3399.PubMed

87.

Kang BY, Chung SW, Im SY, Choe YK, Kim TS: Sulfasalazine prevents T-helper 1 immune response by suppressing interleukin-12 production in macrophages. Immunology. 1999, 98: 98-103.PubMedCentralPubMed

88.

Constantin A, Loubet-Lescoulie P, Lambert N, Yassine-Diab B, Abbal M, Mazieres B, de Preval C, Cantagrel A: Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: evidence of increased inter-leukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction. Arthritis Rheum. 1998, 41: 48-57.PubMed

89.

de Groot K, Gross WL: Wegener's granulomatosis: disease course, assessment of activity and extent and treatment. Lupus. 1998, 7: 285-291.PubMed

90.

Morinobu A, Wang Z, Kumagai S: Bucillamine suppresses human Th1 cell development by a hydrogen peroxide-independent mechanism. J Rheumatol. 2000, 27: 851-858.PubMed

91.

Almawi WY, Melemedjian OK, Rieder MJ: An alternate mechanism of glucocorticoid anti-proliferative effect: promotion of a Th2 cytokine-secreting profile. Clin Transplant. 1999, 13: 365-374.PubMed

92.

Ranges GE, Sriram S, Cooper SM: Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med. 1985, 162: 1105-1110.PubMed

93.

Waldor MK, Sriram S, Hardy R, Herzenberg LA, Lanier L, Lim M, Steinman L: Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker. Science. 1985, 227: 415-417.PubMed

94.

Wofsy D, Seaman WE: Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. J Immunol. 1987, 138: 3247-3253.PubMed

95.

Schulze-Koops H, Davis LS, Haverty TP, Wacholtz MC, Lipsky PE: Reduction of Th1 cell activity in the peripheral circulation of patients with rheumatoid arthritis after treatment with a non-depleting humanized monoclonal antibody to CD4. J Rheumatol. 1998, 25: 2065-2076.PubMed

96.

Ellis CN, Krueger GG: Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med. 2001, 345: 248-255.PubMed

97.

Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, Menter A, Lowe NJ, Krueger G, Brown MJ, et al: CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest. 1999, 103: 1243-1252.PubMedCentralPubMed

98.

Moreland LW, Alten R, Van Den Bosch F, Appelboom T, Leon M, Emery P, Cohen S, Luggen M, Shergy W, Nuamah I, et al: Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002, 46: 1470-1479.PubMed

99.

Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, et al: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003, 349: 1907-1915.PubMed

100.

Kavanaugh AF, Lightfoot E, Lipsky PE, Oppenheimer-Marks N: The role of CD11/CD18 in adhesion and transendothelial migration of T cells: analysis utilizing CD18 deficient T cell clones. J Immunol. 1991, 146: 4149-4156.PubMed

101.

Kavanaugh AF, Davis LS, Nichols LA, Norris SH, Rothlein R, Scharschmidt LA, Lipsky PE: Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum. 1994, 37: 992-999.PubMed

Title: The role of the T cell in autoimmune inflammation
Authors: Alla Skapenko
Jan Leipe
Peter E Lipsky
Hendrik Schulze-Koops
Publication date: 01-03-2005
Publisher: BioMed Central
Published in: Arthritis Research & Therapy / Issue Special Issue 2/2005
Electronic ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar1703

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials